<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antidiabetics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int264-antidiabetics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int264-antidiabetics.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int264-antidiabetics.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int263-tryptophan.htm" title="Previous: Tryptophan">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1239-dapagliflozin.htm" title="Next: Dapagliflozin">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Antidiabetics</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Antidiabetics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>enhanced by</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int36-anabolic-steroids.htm">Anabolic Steroids</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>possibly enhanced by</span> <span>anabolic steroids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>warning signs of hypoglycaemia (such as tremor) with </span><span>antidiabetics</span> <span>may be masked when given with</span> <span>beta-blockers</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>corticosteroids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>diazoxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>thiazides and related diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>possibly enhanced by</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>oestrogens</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int1232-pasireotide.htm">Pasireotide</a></td><td><p><span>requirements for </span><span>antidiabetics</span> <span>possibly reduced by</span> <span>pasireotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>antagonised by</span> <span>progestogens</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int814-testosterone.htm">Testosterone</a></td><td><p><span>hypoglycaemic effect of </span><span>antidiabetics</span> <span>possibly enhanced by</span> <span>testosterone</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Dapagliflozin</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span></span> <span>dapagliflozin</span> <span>possibly enhances diuretic effect of</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span></span> <span>dapagliflozin</span> <span>possibly enhances diuretic effect of</span> <span>thiazides and related diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int911-pioglitazone.htm">Pioglitazone</a></td><td><p><span>manufacturer of </span><span>dapagliflozin</span> <span>advises avoid concomitant use with</span> <span>pioglitazone</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Linagliptin</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>effects of </span><span>linagliptin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Liraglutide</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Saxagliptin</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Vildagliptin</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Exenatide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Other oral drugs may be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>exenatide</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sitagliptin</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>sitagliptin</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Acarbose</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>hypoglycaemic effect of </span><span>acarbose</span> <span>possibly enhanced by</span> <span>colestyramine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>acarbose</span> <span>possibly reduces plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>hypoglycaemic effect of </span><span>acarbose</span> <span>possibly enhanced by</span> <span>neomycin</span><span>, also severity of gastro-intestinal effects increased</span></p></td><td></td></tr><tr><td><a href="bnf_int856-orlistat.htm">Orlistat</a></td><td><p><span>avoidance of </span><span>acarbose</span> <span>advised by manufacturer of</span> <span>orlistat</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int645-pancreatin.htm">Pancreatin</a></td><td><p><span>hypoglycaemic effect of </span><span>acarbose</span> <span>antagonised by</span> <span>pancreatin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Insulin</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>hypoglycaemic effect of </span><span>insulin</span> <span>possibly enhanced by</span> <span>ACE inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>hypoglycaemic effect of </span><span>insulin</span> <span>enhanced by</span> <span>beta-blockers</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td><p><span>hypoglycaemic effect of </span><span>insulin</span> <span>possibly enhanced by</span> <span>disopyramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td><p><span>may be improved glucose tolerance and an additive effect when </span><span>insulin</span> <span>given with</span> <span>fibrates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int866-lanreotide.htm">Lanreotide</a></td><td><p><span>requirements for </span><span>insulin</span> <span>possibly reduced by</span> <span>lanreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>hypoglycaemic effect of </span><span>insulin</span> <span>enhanced by</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span>glucose tolerance occasionally impaired when </span><span>insulin</span> <span>given with</span> <span>nifedipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td><p><span>requirements for </span><span>insulin</span> <span>possibly reduced by</span> <span>octreotide</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Nateglinide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>hypoglycaemic effect of </span><span>nateglinide</span> <span>possibly enhanced by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td><p><span>hypoglycaemic effect of </span><span>nateglinide</span> <span>possibly enhanced by</span> <span>gemfibrozil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>nateglinide</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Repaglinide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>hypoglycaemic effect of </span><span>repaglinide</span> <span>possibly enhanced by</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>effects of </span><span>repaglinide</span> <span>enhanced by</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1072-deferasirox.htm">Deferasirox</a></td><td><p><span>plasma concentration of </span><span>repaglinide</span> <span>increased by</span> <span>deferasirox</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>increased risk of severe hypoglycaemia when </span><span>repaglinide</span> <span>given with</span> <span>gemfibrozil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>hypoglycaemic effect of </span><span>repaglinide</span> <span>possibly enhanced by</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int866-lanreotide.htm">Lanreotide</a></td><td><p><span>requirements for </span><span>repaglinide</span> <span>possibly reduced by</span> <span>lanreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>repaglinide</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td><p><span>requirements for </span><span>repaglinide</span> <span>possibly reduced by</span> <span>octreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>hypoglycaemic effect of </span><span>repaglinide</span> <span>possibly antagonised by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>hypoglycaemic effect of </span><span>repaglinide</span> <span>possibly enhanced by</span> <span>trimethoprim</span><span>—manufacturer advises avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Biguanides</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Metformin</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>hypoglycaemic effect of </span><span>metformin</span> <span>possibly enhanced by</span> <span>ACE inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>increased risk of lactic acidosis when </span><span>metformin</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>excretion of </span><span>metformin</span> <span>reduced by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td><p><span>hypoglycaemic effect of </span><span>metformin</span> <span>possibly enhanced by</span> <span>disopyramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int789-ketotifen.htm">Ketotifen</a></td><td><p><span>thrombocyte count depressed when </span><span>metformin</span> <span>given with</span> <span>ketotifen</span> <span>(manufacturer of <span>ketotifen</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int866-lanreotide.htm">Lanreotide</a></td><td><p><span>requirements for </span><span>metformin</span> <span>possibly reduced by</span> <span>lanreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>hypoglycaemic effect of </span><span>metformin</span> <span>enhanced by</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td><p><span>requirements for </span><span>metformin</span> <span>possibly reduced by</span> <span>octreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td><p><span>plasma concentration of </span><span>metformin</span> <span>possibly increased by</span> <span>rilpivirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td><p><span>plasma concentration of </span><span>metformin</span> <span>possibly increased by</span> <span>topiramate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sulfonylureas</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>hypoglycaemic effect of </span><span>sulfonylureas</span> <span>possibly enhanced by</span> <span>ACE inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td class="cAI"><p><span>effects of </span><span>sulfonylureas</span> <span>enhanced by</span> <span>chloramphenicol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>hypoglycaemic effect of </span><span>sulfonylureas</span> <span>enhanced by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span>hypoglycaemic effect of  </span><span>sulfonylureas</span> <span>possibly enhanced by</span> <span>coumarins</span><span>, also possible changes to anticoagulant effect</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td><p><span>may be improved glucose tolerance and an additive effect when </span><span>sulfonylureas</span> <span>given with</span> <span>fibrates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>sulfonylureas</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int866-lanreotide.htm">Lanreotide</a></td><td><p><span>requirements for </span><span>sulfonylureas</span> <span>possibly reduced by</span> <span>lanreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>hypoglycaemic effect of </span><span>sulfonylureas</span> <span>enhanced by</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>sulfonylureas</span> <span>increased by</span> <span>miconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>effects of </span><span>sulfonylureas</span> <span>possibly enhanced by</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td><p><span>requirements for </span><span>sulfonylureas</span> <span>possibly reduced by</span> <span>octreotide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td><p><span>hypoglycaemic effect of </span><span>sulfonylureas</span> <span>possibly antagonised by</span> <span>phenothiazines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span><span>sulfonylureas</span> <span>possibly accelerated by</span> <span>rifamycins</span> <span>(reduced effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td class="cAI"><p><span>effects of </span><span>sulfonylureas</span> <span>enhanced by</span> <span>sulfinpyrazone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td><p><span>effects of </span><span>sulfonylureas</span> <span>rarely enhanced by</span> <span>sulfonamides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int209-tetracyclines.htm">Tetracyclines</a></td><td><p><span>hypoglycaemic effect of </span><span>sulfonylureas</span> <span>possibly enhanced by</span> <span>tetracyclines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>effects of </span><span>sulfonylureas</span> <span>rarely enhanced by</span> <span>trimethoprim</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span>plasma concentration of </span><span>sulfonylureas</span> <span>possibly increased by</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Glibenclamide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span>increased risk of hepatotoxicity when </span><span>glibenclamide</span> <span>given with</span> <span>bosentan</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1108-colesevelam.htm">Colesevelam</a></td><td><p><span>absorption of </span><span>glibenclamide</span> <span>reduced by</span> <span>colesevelam</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td><p><span>plasma concentration of </span><span>glibenclamide</span> <span>possibly increased by</span> <span>fluvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int197-norfloxacin.htm">Norfloxacin</a></td><td><p><span>effects of </span><span>glibenclamide</span> <span>possibly enhanced by</span> <span>norfloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td><p><span>plasma concentration of </span><span>glibenclamide</span> <span>possibly reduced by</span> <span>topiramate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Gliclazide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td><p><span>hypoglycaemic effect of </span><span>gliclazide</span> <span>possibly enhanced by</span> <span>disopyramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>hypoglycaemic effect of </span><span>gliclazide</span> <span>enhanced by</span> <span>miconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Glimepiride</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Glipizide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>hypoglycaemic effect of </span><span>glipizide</span> <span>enhanced by</span> <span>miconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td><p><span>hypoglycaemic effect of </span><span>glipizide</span> <span>possibly enhanced by</span> <span>posaconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tolbutamide</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span>plasma concentration of </span><span>tolbutamide</span> <span>reduced by</span> <span>aprepitant</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td><p><span>hypoglycaemic effect of </span><span>tolbutamide</span> <span>possibly enhanced by</span> <span>leflunomide</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>tolbutamide</span> <span>transiently increases plasma concentration of</span> <span>phenytoin</span> <span>(possibility of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span><span>tolbutamide</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>tolbutamide</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Thiazolidinediones</strong> belongs to <strong>Antidiabetics</strong> but has no specific interaction information.</p><p><strong>Pioglitazone</strong> belongs to <strong>Antidiabetics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1239-dapagliflozin.htm">Dapagliflozin</a></td><td><p><span>avoidance of </span><span>pioglitazone</span> <span>advised by manufacturer of</span> <span>dapagliflozin</span> <span></span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1239-dapagliflozin.htm" title="Dapagliflozin">Dapagliflozin</a></li><li><a href="bnf_int1210-linagliptin.htm" title="Linagliptin">Linagliptin</a></li><li><a href="bnf_int1157-liraglutide.htm" title="Liraglutide">Liraglutide</a></li><li><a href="bnf_int1156-saxagliptin.htm" title="Saxagliptin">Saxagliptin</a></li><li><a href="bnf_int1113-vildagliptin.htm" title="Vildagliptin">Vildagliptin</a></li><li><a href="bnf_int1090-exenatide.htm" title="Exenatide">Exenatide</a></li><li><a href="bnf_int1089-sitagliptin.htm" title="Sitagliptin">Sitagliptin</a></li><li><a href="bnf_int1-acarbose.htm" title="Acarbose">Acarbose</a></li><li><a href="bnf_int265-insulin.htm" title="Insulin">Insulin</a></li><li><a href="bnf_int920-nateglinide.htm" title="Nateglinide">Nateglinide</a></li><li><a href="bnf_int855-repaglinide.htm" title="Repaglinide">Repaglinide</a></li><li id="_bnf_int266-biguanides"><a href="bnf_int266-biguanides.htm" title="Biguanides">Biguanides</a></li><li id="_bnf_int268-sulfonylureas"><a href="bnf_int268-sulfonylureas.htm" title="Sulfonylureas">Sulfonylureas</a></li><li id="_bnf_int910-thiazolidinediones"><a href="bnf_int910-thiazolidinediones.htm" title="Thiazolidinediones">Thiazolidinediones</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int263-tryptophan.htm">Previous: Tryptophan</a> | <a class="top" href="bnf_int264-antidiabetics.htm#">Top</a> | <a accesskey="]" href="bnf_int1239-dapagliflozin.htm">Next: Dapagliflozin</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>